Literature DB >> 1143006

3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier.

L A Wade, R Katzman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1143006     DOI： 10.1016/0024-3205(75)90248-9

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


× No keyword cloud information.
  32 in total

Review 1.  Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives.

Authors:  Khosro Jamebozorgi; Eskandar Taghizadeh; Daryoush Rostami; Hosein Pormasoumi; George E Barreto; Seyed Mohammad Gheibi Hayat; Amirhossein Sahebkar
Journal:  Mol Neurobiol       Date:  2018-11-05       Impact factor: 5.590

2.  Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.

Authors:  H Baas; A G Beiske; J Ghika; M Jackson; W H Oertel; W Poewe; G Ransmayr
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 3.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

4.  Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-06       Impact factor: 2.745

5.  In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study.

Authors:  D Deleu; S Sarre; G Ebinger; Y Michotte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

6.  Diurnal differences in response to oral levodopa.

Authors:  J P Frankel; Z Pirtosek; P A Kempster; M Bovingdon; R Webster; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

7.  Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.

Authors:  Siegfried Muhlack; Lennard Herrmann; Stephan Salmen; Thomas Müller
Journal:  J Neural Transm (Vienna)       Date:  2014-04-26       Impact factor: 3.575

8.  Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.

Authors:  T Keränen; A Gordin; M Karlsson; K Korpela; P J Pentikäinen; H Rita; E Schultz; L Seppälä; T Wikberg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.

Authors:  Luis Almeida; José Francisco Rocha; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

10.  Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

Authors:  José Francisco Rocha; Luis Almeida; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.